{"id":2797,"date":"2017-09-05T14:45:16","date_gmt":"2017-09-05T14:45:16","guid":{"rendered":"http:\/\/www.caltagmedsystems.co.uk\/information\/?p=2797"},"modified":"2017-09-05T14:45:16","modified_gmt":"2017-09-05T14:45:16","slug":"news-release-journal-article-highlights-albuvoid-in-cancer-functional-proteomic-analysis","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/news-release-journal-article-highlights-albuvoid-in-cancer-functional-proteomic-analysis\/","title":{"rendered":"News Release Journal Article Highlights AlbuVoid\u2122 in Cancer Functional Proteomic Analysis"},"content":{"rendered":"

Biotech Support Group reports on a new research report which highlights the simplicity and efficiency of their proteomic sample preparation technology as an initial enrichment step to the Array Bridge (St. Louis, MO) Protein Elution Plate (PEP). The combined methods support functional proteomic profiling of breast cancer sera. The citation is:<\/span><\/span><\/p>\n

David L. Wang, Chuanguang Xiao, Guofeng Fu, Xing Wang and Liang Li<\/span><\/span><\/span>.<\/span><\/span><\/span>\u00a0<\/span><\/span>Identification of potential serum biomarkers for breast cancer using a functional proteomics technology. Biomarker Research (2017) 5:11.\u00a0<\/span><\/span><\/span>DOI 10.1186\/s40364-017-0092-9<\/span><\/span><\/a><\/u><\/span><\/p>\n

In this study, a functional proteomics technology was used to systematically monitor metabolic enzyme and protease activities from resolved serum proteins produced by a modified 2-D gel separation and subsequent Protein Elution Plate, a method collectively called PEP.\u00a0<\/span><\/span>AlbuVoid\u2122<\/b><\/span>\u00a0was used to remove Albumin and enrich the low abundance serum proteome. The article states \u201c<\/span>The most dramatic difference for enzyme activity detection in using the\u00a0<\/span><\/span>AlbuVoid<\/b><\/span><\/span>\u2122<\/b><\/span><\/span>\u00a0<\/span><\/span>for serum protein enrichment was demonstrated. \u2026 Compared with the direct serum proteinase measurement, both the levels and species of proteases were increased significantly in the enriched serum sample. \u2026protease activity in the direct serum analysis suggested that the protease levels in the serum were below the detection threshold of protease activity\u2026,and it is necessary to use\u00a0<\/span><\/span>AlbuVoid<\/b><\/span><\/span>\u2122<\/b><\/span><\/span>\u00a0<\/span><\/span>to enrich these low level proteases to bring them to a high enough level to be detected.\u201d Both qualitative and quantitative differences in the metabolic enzyme and protease activity were detected between breast cancer patient and control group, providing excellent biomarker candidates for breast cancer diagnosis and drug development.<\/span><\/span><\/span><\/p>\n

\u201cWe are very pleased to see that AlbuVoid\u2122 provided the enrichment necessary to uncover biomarker candidates for cancer using the PEP platform. A key feature in all of our products is to not only separate proteomes but to retain the functional features of proteins after separations. This is important as protein conformations is highly variable, each conformation contributes to its own unique functional activity. AlbuVoid\u2122 enrichment followed by PEP can profile these functional activities\u201d states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.<\/span><\/span><\/p>\n

For more information on AlbuVoid\u2122, go to:\u00a0<\/span>http:\/\/www.biotechsupportgroup.com\/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p\/avk.htm<\/a><\/span><\/u><\/span><\/p>\n

About Biotech Support Group LLC<\/b><\/span><\/span><\/h4>\n

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid\u2122 and AlbuSorb\u2122 for albumin depletion, Cleanascite\u2122 for lipid adsorption, HemogloBind\u2122 and HemoVoid\u2122 for hemoglobin removal, and NuGel\u2122 for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to<\/span><\/span>\u00a0<\/span><\/span><\/span>http:\/\/www.biotechsupportgroup.com<\/span><\/span><\/span><\/a><\/u><\/span>\u00a0<\/span><\/span><\/span><\/span><\/p>\n

Originally posted on 8th December 2015:\u00a0http:\/\/www.biotechsupportgroup.com\/Articles.asp?ID=462<\/p>\n

Biotech Support Group is distributed by Caltag Medsystems, to see more click here<\/a>.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech Support Group reports on a new research report which highlights the simplicity and efficiency of their proteomic sample preparation technology as an initial enrichment step to the Array Bridge (St. Louis, MO) Protein Elution Plate (PEP). The combined methods<\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[362,357,7,363],"class_list":["post-2797","post","type-post","status-publish","format-standard","hentry","category-general-information","tag-albuvoid","tag-biotech-support-group","tag-cancer","tag-cancer-proteomic-analysis"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/2797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=2797"}],"version-history":[{"count":1,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/2797\/revisions"}],"predecessor-version":[{"id":2798,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/2797\/revisions\/2798"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=2797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=2797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=2797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}